Skip to main content

Table 6 Relapse-free and overall survival with respect to biomarker score for test and validation sets

From: Can clinically relevant prognostic subsets of breast cancer patients with four or more involved axillary lymph nodes be identified through immunohistochemical biomarkers? A tissue microarray feasibility study

Survival

Division

Test set

Validation set

  

n

Median RFS, years (95% CI)

10-year RFS, percentage (SEM)

n

Median RFS, years (95% CI)

10 year RFS, percentage (SEM)

RFS

Overall cohort

313

5.2 (3.9–6.5)

38.3 (2.9)

289

5.8 (4.4–7.3)

38.1 (2.9)

 

0

38/227

NR

75.4 (7.1)

40/219

9.7 (5.5–14.0)

47.8 (8.4)

 

1–4

154/227

4.8 (3.6–6.1)

35.3 (4.1)

146/219

5.8 (3.9–7.7)

37.8 (4.2)

 

5–8

35/227

1.6 (0.8–2.3)

19.3 (7.0)

33/219

2.4 (0.9–3.8)

30.3 (8.0)

 

All markers

227/227

5.2 (3.6–6.9)

39.8 (3.4)

219/219

5.8 (4.2–7.5)

38.5 (3.4)

OS

Overall cohort

313

6.7 (5.7–7.8)

39.5 (3.4)

289

7.3 (5.9–8.6)

39.1 (2.9)

 

0

38/227

15.5 (10.9–20.1)

67.6 (7.7)

40/219

9.3 (5.5–13.1)

47.5 (7.9)

 

1–4

154/227

6.4 (5.3–7.5)

35.1 (3.8)

146/219

7.8 (5.8–9.9)

38.4 (4.0)

 

5–8

35/227

2.7 (1.1–4.3)

21.6 (6.8)

33/219

3.3 (1.7–4.9)

30.3 (8.0)

 

All markers

227/227

6.6 (5.2–8.0)

38.2 (3.2)

219/219

7.6 (6.0–9.1)

38.8 (3.3)

  1. Relapse-free and overall survival are presented in the test and validation sets for the overall cohorts, for the subsets with expression scores available for all eight biomarkers assessed and with respect to patient subgroups for biomarker scores of 0, 1 to 4, and 5 to 8. RFS, relapse-free survival; OS, overall survival; NR, not reached; CI, confidence interval.